BioSpace News Archive

Gilead Sciences, Inc. announced that Mark Genovese, MD, has been appointed Senior Vice President, Inflammation, with responsibility for overseeing the clinical development of the company’s investigational portfolio of treatments for inflammatory conditions.

Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of inducement awards to both its Chief Scientific Officer, Virology, William Delaney, Ph.D., and eight new employees on May 27, 2020 and June 1, 2020, respectively.

Nordson Corporation has acquired Fluortek, Inc., an Easton, Pennsylvania based precision plastic extrusion manufacturer that provides custom dimensioned tubing to the medical device industry.

The WHO says that oral diseases are the fourth-most expensive disease to treat across the world. Therefore, oral health maintenance expenditure is a huge healthcare concern impacting both developed and developing countries.

MedX Health Corp. is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.

Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $84.00 per share,

NDA is supported by positive data from two Phase 3 studies and a long-term extension study, demonstrating sustained reduction in heavy menstrual bleeding while maintaining bone health through one year If approved, relugolix combination tablet would be the first once-daily, oral treatment for women with heavy menstrual bleeding associated with uterine fibroids in the U.S. BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on